Tagrisso (osimertinib) improves cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 Phase III clinical trial presented on Friday at the European Lung Cancer Conference.
The analysis is further good news for Anglo-Swedish pharma major AstraZeneca (LSE: AZN) on Tagrisso, which last month received full marketing authorization for a lung cancer indication from the European Commission based on results from the AURA3 study.
For patients with incurable cancer, prolonging only progression-free survival probably has little meaning. However, treatment that can additionally improve symptoms and maintain quality of life means a lot"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze